CheckMate-498 is evaluating the efficacy of nivolumab versus TMZ, both with concurrent radiotherapy, in patients with newly diagnosed GBM with unmethylated O6-methylguanine-DNA methyltransferase (MGMT), while the CheckMate-548 trial (NCT02667587) is assessing the combination treatment of nivolumab with standard radiotherapy and TMZ followed by adjuvant TMZ with nivolumab in newly diagnosed GBM with methylated MGMT promoter. This evidence concerns the gene MGMT and glioblastoma.